Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

when they sold the foreign rights they made themselves a lot less appealing to major BP companies

Probably not. If you look at the history of pharma selling foreign rights for their drugs, it reveals that deal values for foreign rights go down after P3 approval. Getting a deal done pre-approval looks like a smart move.

I see zero indication Aurinia is pursuing a GIA strategy. I see them trying to maximize their value for a BO. It's impossible for anyone to value VCS without knowing if the label is 2027 or 2037. The value differential is enormous and BP doesn't want to take the big gamble of paying full value for such a huge unknown.

Aurinia is not sitting around on their hands hoping to be sold- they're going full bore ready to take the drug to market on day 1 of approval. The odds are high one or more BP's will want to buy VCS, maybe even GSK since Benlysta is a joke.